secwatch / observer
8-K filed April 3, 2023, 7:59 PM ET ticker BMEA CIK 0001840439
other material confidence high sentiment neutral materiality 0.80

Biomea Fusion prices upsized $150M public offering of 5M shares at $30; net proceeds ~$161.6M

Biomea Fusion, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Biomea Fusion, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Citigroup Global Markets Inc. valued at 5,000,000 shares of common stock at $30.00 per share, with option for additional 750,000 shares, agg (effective 2023-03-29).

Action
entry
Agreement
underwriting
Counterparty
J.P. Morgan Securities LLC and Citigroup Global Markets Inc.
Value
5,000,000 shares of common stock at $30.00 per share, with option for additional 750,000 shares, agg
Effective
2023-03-29
Exact text from the filing
On March 29, 2023, Biomea Fusion, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreemen t ”) with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein (the “Underwriters”) pursuant to which the Company agreed to issue and sell 5,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), to the Underwriters at a public offering price of $30.00 per share (the “Offering”). Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 750,000 shares of Common Stock at the same price per share (the “Option Shares”).
View on SEC.gov

245 material agreements filed in the last 30 days. Browse all material agreements →

Biomea Fusion, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-089530
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.